| 1 |
Elbaz A , Grigoletto F , Baldereschi M , Breteler MM , Manubens-Bertran JM , Lopez-Pousa S , Dartigues JF , Alpérovitch A , Tzourio C , Rocca WA , EUROPARKINSON Study Group . Familial aggregation of Parkinson's disease: a population-based case-control study in Europe. Neurology, 1999, 52: 1876- 1882.
doi: 10.1212/WNL.52.9.1876
|
| 2 |
Schrag A , Schott JM . Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol, 2006, 5: 355- 363.
doi: 10.1016/S1474-4422(06)70411-2
|
| 3 |
Lunati A , Lesage S , Brice A . The genetic landscape of Parkinson's disease. Rev Neurol (Paris), 2018, 174: 628- 643.
doi: 10.1016/j.neurol.2018.08.004
|
| 4 |
Ortega RA , Wang C , Raymond D , Bryant N , Scherzer CR , Thaler A , Alcalay RN , West AB , Mirelman A , Kuras Y , Marder KS , Giladi N , Ozelius LJ , Bressman SB , Saunders-Pullman R . Association of dual LRRK2 G2019S and GBA variations with Parkinson disease progression. JAMA Netw Open, 2021, 4: e215845.
doi: 10.1001/jamanetworkopen.2021.5845
|
| 5 |
Di Fonzo A , Rohé CF , Ferreira J , Chien HF , Vacca L , Stocchi F , Guedes L , Fabrizio E , Manfredi M , Vanacore N , Goldwurm S , Breedveld G , Sampaio C , Meco G , Barbosa E , Oostra BA , Bonifati V , Italian Parkinson Genetics Network . A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet, 2005, 365: 412- 415.
|
| 6 |
Tolosa E , Vila M , Klein C , Rascol O . LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol, 2020, 16: 97- 107.
doi: 10.1038/s41582-019-0301-2
|
| 7 |
Yang N , Zhao Y , Liu Z , Zhang R , He Y , Zhou Y , Xu Q , Sun Q , Yan X , Guo J , Tang B . Systematically analyzing rare variants of autosomal-dominant genes for sporadic Parkinson's disease in a Chinese cohort. Neurobiol Aging, 2019, 76: 215.e1- 215.e7.
doi: 10.1016/j.neurobiolaging.2018.11.012
|
| 8 |
Riboldi GM , Frattini E , Monfrini E , Frucht SJ , Di Fonzo A . A practical approach to early-onset parkinsonism. J Parkinsons Dis, 2022, 12: 1- 26.
doi: 10.3233/JPD-212815
|
| 9 |
Healy DG , Falchi M , O'Sullivan SS , Bonifati V , Durr A , Bressman S , Brice A , Aasly J , Zabetian CP , Goldwurm S , Ferreira JJ , Tolosa E , Kay DM , Klein C , Williams DR , Marras C , Lang AE , Wszolek ZK , Berciano J , Schapira AH , Lynch T , Bhatia KP , Gasser T , Lees AJ , Wood NW , International LRRK2 Consortium . Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol, 2008, 7: 583- 590.
doi: 10.1016/S1474-4422(08)70117-0
|
| 10 |
Pankratz N , Foroud T . Genetics of Parkinson disease. Genet Med, 2007, 9: 801- 811.
doi: 10.1097/GIM.0b013e31815bf97c
|
| 11 |
Wang C , Cai Y , Gu Z , Ma J , Zheng Z , Tang BS , Xu Y , Zhou Y , Feng T , Wang T , Chen SD , Chan P , Chinese Parkinson Study Group . Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals. Neurobiol Aging, 2014, 35: 725.e1- 725.e6.
doi: 10.1016/j.neurobiolaging.2013.08.012
|
| 12 |
Smith L , Schapira AHV . GBA variants and Parkinson disease: mechanisms and treatments. Cells, 2022, 11: 1261.
doi: 10.3390/cells11081261
|
| 13 |
Gámez-Valero A , Prada-Dacasa P , Santos C , Adame-Castillo C , Campdelacreu J , Reñé R , Gascón-Bayarri J , Ispierto L , Álvarez R , Ariza A , Beyer K . GBA mutations are associated with earlier onset and male sex in dementia with Lewy bodies. Mov Disord, 2016, 31: 1066- 1070.
doi: 10.1002/mds.26593
|
| 14 |
Gegg ME , Burke D , Heales SJ , Cooper JM , Hardy J , Wood NW , Schapira AH . Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann Neurol, 2012, 72: 455- 463.
doi: 10.1002/ana.23614
|
| 15 |
Lim JL , Lohmann K , Tan AH , Tay YW , Ibrahim KA , Abdul Aziz Z , Mawardi AS , Puvanarajah SD , Lim TT , Looi I , Ooi JCE , Chia YK , Muthusamy KA , Bauer P , Rolfs A , Klein C , Ahmad-Annuar A , Lim SY . Glucocerebrosidase (GBA) gene variants in a multi-ethnic Asian cohort with Parkinson's disease: mutational spectrum and clinical features. J Neural Transm (Vienna), 2022, 129: 37- 48.
doi: 10.1007/s00702-021-02421-0
|
| 16 |
Yahalom G , Greenbaum L , Israeli-Korn S , Fay-Karmon T , Livneh V , Ruskey JA , Roncière L , Alam A , Gan-Or Z , Hassin-Baer S . Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: risk estimates and genotype-phenotype correlations. Parkinsonism Relat Disord, 2019, 62: 179- 184.
doi: 10.1016/j.parkreldis.2018.12.014
|
| 17 |
Goldstein O , Gana-Weisz M , Cohen-Avinoam D , Shiner T , Thaler A , Cedarbaum JM , John S , Lalioti M , Gurevich T , Bar-Shira A , Mirelman A , Giladi N , Orr-Urtreger A . Revisiting the non-Gaucher-GBA-E326K carrier state: is it sufficient to increase Parkinson's disease risk. ? Mol Genet Metab, 2019, 128: 470- 475.
doi: 10.1016/j.ymgme.2019.10.001
|
| 18 |
Omer N , Giladi N , Gurevich T , Bar-Shira A , Gana-Weisz M , Goldstein O , Kestenbaum M , Cedarbaum JM , Orr-Urtreger A , Mirelman A , Thaler A . A possible modifying effect of the G2019S mutation in the LRRK2 gene on GBA Parkinson's disease. Mov Disord, 2020, 35: 1249- 1253.
doi: 10.1002/mds.28066
|
| 19 |
Tang Y , Wei L , Wu Z , Xu P , Mo M . Parkinson's disease in a patient with GBA and LRRK2 covariants after acute hypoxic insult: a case report. BMC Neurol, 2023, 23: 226.
doi: 10.1186/s12883-023-03269-5
|
| 20 |
Akdemir ÜÖ , Bora Tokçaer A , Atay LÖ . Dopamine transporter SPECT imaging in Parkinson's disease and parkinsonian disorders. Turk J Med Sci, 2021, 51: 400- 410.
doi: 10.3906/sag-2008-253
|
| 21 |
Postuma RB , Berg D , Stern M , Poewe W , Olanow CW , Oertel W , Obeso J , Marek K , Litvan I , Lang AE , Halliday G , Goetz CG , Gasser T , Dubois B , Chan P , Bloem BR , Adler CH , Deuschl G . MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord, 2015, 30: 1591- 1601.
doi: 10.1002/mds.26424
|
| 22 |
Rogers G , Davies D , Pink J , Cooper P . Parkinson's disease: summary of updated NICE guidance. BMJ, 2017, 358: j1951.
|
| 23 |
Brüggemann N , Klein C . Will genotype drive treatment options. ? Mov Disord, 2019, 34: 1294- 1299.
doi: 10.1002/mds.27699
|
| 24 |
Poortvliet PC , O'Maley K , Silburn PA , Mellick GD . Perspective: current pitfalls in the search for future treatments and prevention of Parkinson's disease. Front Neurol, 2020, 11: 686.
doi: 10.3389/fneur.2020.00686
|
| 25 |
Prasuhn J , Brüggemann N . Genotype-driven therapeutic developments in Parkinson's disease. Mol Med, 2021, 27: 42.
|
| 26 |
Chinese Society of Parkinson's Disease and Movement Disorders , Parkinson's Disease and Movement Disorder Section of Neurologist Branch of Chinese Medical Doctor Association . Chinese guidelines for the treatment of Parkinson's disease (fourth edition). Zhonghua Shen Jing Ke Za Zhi, 2020, 53: 973- 986.
|
|
中华医学会神经病学分会帕金森病及运动障碍学组, 中国医师协会神经内科医师分会帕金森病及运动障碍学组. 中国帕金森病治疗指南(第四版). 中华神经科杂志, 2020, 53: 973- 986.
|
| 27 |
Zhang Y , Sun QY , Zhao YW , Shu L , Guo JF , Xu Q , Yan XX , Tang BS . Effect of GBA mutations on phenotype of Parkinson's disease: a study on Chinese population and a Meta-analysis. Parkinsons Dis, 2015, ID916971.
|
| 28 |
Biswas A , Sadhukhan D , Biswas A , Das SK , Banerjee TK , Bal PS , Pal S , Ghosh A , Ray K , Ray J . Identification of GBA mutations among neurodegenerative disease patients from eastern India. Neurosci Lett, 2021, 751: 135816.
doi: 10.1016/j.neulet.2021.135816
|
| 29 |
Salamon A , Zádori D , Szpisjak L , Klivényi P , Vécsei L . The genetic background of Parkinson's disease and novel therapeutic targets. Expert Opin Ther Targets, 2022, 26: 827- 836.
doi: 10.1080/14728222.2022.2153037
|